uniQure N.V. (QURE)
Largest Insider Buys in Sector
QURE Stock Price History Chart
QURE Stock Performance
About uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the …
Insider Activity of uniQure N.V.
Over the last 12 months, insiders at uniQure N.V. have bought $0 and sold $489,709 worth of uniQure N.V. stock.
On average, over the past 5 years, insiders at uniQure N.V. have bought $0 and sold $7.68M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, uniQure N.V.
| 2024-06-26 | Sale | Chief Medical Officer | 1,447 0.003% | $4.36 | $6,309 | +40.68% | ||
| 2024-06-17 | Sale | Chief Financial Officer | 1,611 0.003% | $4.80 | $7,733 | +29.42% | ||
| 2024-06-17 | Sale | Chief Operating Officer | 2,936 0.0056% | $4.81 | $14,122 | +29.42% | ||
| 2024-06-13 | Sale | Chief Legal Officer | 4,781 0.0094% | $4.98 | $23,809 | +12.76% | ||
| 2024-06-13 | Sale | director | 3,504 0.0071% | $5.12 | $17,940 | +12.76% | ||
| 2024-06-13 | Sale | director | 2,231 0.0045% | $5.12 | $11,423 | +12.76% | ||
| 2024-06-13 | Sale | director | 2,231 0.0045% | $5.12 | $11,423 | +12.76% | ||
| 2024-06-13 | Sale | director | 2,229 0.0045% | $5.12 | $11,412 | +12.76% | ||
| 2024-06-13 | Sale | director | 2,220 0.0045% | $5.14 | $11,411 | +12.76% | ||
| 2024-06-13 | Sale | director | 2,222 0.0045% | $5.14 | $11,421 | +12.76% | ||
| 2024-06-13 | Sale | director | 2,221 0.0045% | $5.14 | $11,416 | +12.76% | ||
| 2024-06-13 | Sale | director | 2,218 0.0045% | $5.16 | $11,445 | +12.76% | ||
| 2024-02-26 | Sale | CEO, Managing Director | 27,904 0.0581% | $6.35 | $177,190 | -16.77% | ||
| 2024-02-26 | Sale | Chief Financial Officer | 15,906 0.0333% | $6.38 | $101,480 | -16.77% | ||
| 2024-02-26 | Sale | Chief Operating Officer | 9,455 0.0201% | $6.47 | $61,174 | -16.77% | ||
| 2023-09-18 | Sale | President, R&D | 5,841 0.0124% | $7.46 | $43,574 | -20.82% | ||
| 2023-07-10 | Sale | Chief Operating Officer | 15,117 0.0313% | $11.36 | $171,729 | -46.49% | ||
| 2023-06-16 | Sale | Chief Financial Officer | 1,587 0.0033% | $18.94 | $30,058 | -67.56% | ||
| 2023-06-16 | Sale | Chief Operating Officer | 2,920 0.0059% | $18.80 | $54,896 | -67.56% | ||
| 2023-06-16 | Sale | director | 3,228 0.0066% | $18.88 | $60,945 | -67.56% |
Institutional Investor Ownership
| Nantahala Capital Management Llc | $16.06M | 6.36 | 3.09M | +4.4% | +$676,285.98 | 0.75 | |
| 683 Capital Management Llc | $10.27M | 4.07 | 1.98M | +16.66% | +$1.47M | 1.11 | |
| BlackRock | $9.68M | 3.83 | 1.86M | +1.31% | +$124,722.00 | <0.0001 | |
| Morgan Stanley | $7.89M | 3.13 | 1.52M | -13.73% | -$1.26M | <0.01 | |
| Schroder Investment Management Group | $6.46M | 2.56 | 1.24M | 0% | +$0 | 0.01 |